Research ExplorerPublicationsBortezomib before and after high-dose therapy in myeloma: lo...

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial

Standard

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. / Goldschmidt, H; Lokhorst, H M; Mai, E K; van der Holt, B; Blau, I W; Zweegman, S; Weisel, K C; Vellenga, E; Pfreundschuh, M; Kersten, M J; Scheid, C; Croockewit, S; Raymakers, R; Hose, D; Potamianou, A; Jauch, A; Hillengass, J; Stevens-Kroef, M; Raab, M S; Broijl, A; Lindemann, H W; Bos, G M J; Brossart, P; van Marwijk Kooy, M; Ypma, P; Duehrsen, U; Schaafsma, R M; Bertsch, U; Hielscher, T; Jarari, Le; Salwender, H J; Sonneveld, P.

In: LEUKEMIA, Vol. 32, No. 2, 02.2018, p. 383-390.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Goldschmidt, H, Lokhorst, HM, Mai, EK, van der Holt, B, Blau, IW, Zweegman, S, Weisel, KC, Vellenga, E, Pfreundschuh, M, Kersten, MJ, Scheid, C, Croockewit, S, Raymakers, R, Hose, D, Potamianou, A, Jauch, A, Hillengass, J, Stevens-Kroef, M, Raab, MS, Broijl, A, Lindemann, HW, Bos, GMJ, Brossart, P, van Marwijk Kooy, M, Ypma, P, Duehrsen, U, Schaafsma, RM, Bertsch, U, Hielscher, T, Jarari, L, Salwender, HJ & Sonneveld, P 2018, 'Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial', LEUKEMIA, vol. 32, no. 2, pp. 383-390. https://doi.org/10.1038/leu.2017.211

APA

Goldschmidt, H., Lokhorst, H. M., Mai, E. K., van der Holt, B., Blau, I. W., Zweegman, S., Weisel, K. C., Vellenga, E., Pfreundschuh, M., Kersten, M. J., Scheid, C., Croockewit, S., Raymakers, R., Hose, D., Potamianou, A., Jauch, A., Hillengass, J., Stevens-Kroef, M., Raab, M. S., ... Sonneveld, P. (2018). Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. LEUKEMIA, 32(2), 383-390. https://doi.org/10.1038/leu.2017.211

Vancouver

Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegman S et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. LEUKEMIA. 2018 Feb;32(2):383-390. https://doi.org/10.1038/leu.2017.211

Bibtex

@article{015522fc99be4f66a879c8e051654e93,
title = "Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial",
abstract = "The Dutch-Belgian Cooperative Trial Group for Hematology Oncology Group-65/German-speaking Myeloma Multicenter Group-HD4 (HOVON-65/GMMG-HD4) phase III trial compared bortezomib (BTZ) before and after high-dose melphalan and autologous stem cell transplantation (HDM, PAD arm) compared with classical cytotoxic agents prior and thalidomide after HDM (VAD arm) in multiple myeloma (MM) patients aged 18-65 years. Here, the long-term follow-up and data on second primary malignancies (SPM) are presented. After a median follow-up of 96 months, progression-free survival (censored at allogeneic transplantation, PFS) remained significantly prolonged in the PAD versus VAD arm (hazard ratio (HR)=0.76, 95% confidence interval (95% CI) of 0.65-0.89, P=0.001). Overall survival (OS) was similar in the PAD versus VAD arm (HR=0.89, 95% CI: 0.74-1.08, P=0.24). The incidence of SPM were similar between the two arms (7% each, P=0.73). The negative prognostic effects of the cytogenetic aberration deletion 17p13 (clone size ⩾10%) and renal impairment at baseline (serum creatinine >2 mg dl-1) on PFS and OS remained abrogated in the PAD but not VAD arm. OS from first relapse/progression was similar between the study arms (HR=1.02, P=0.85). In conclusion, the survival benefit with BTZ induction/maintenance compared with classical cytotoxic agents and thalidomide maintenance is maintained without an increased risk of SPM.",
keywords = "Adolescent, Adult, Aged, Bortezomib, Chromosome Aberrations, Female, Follow-Up Studies, Hematopoietic Stem Cell Transplantation, Humans, Male, Melphalan, Middle Aged, Multiple Myeloma, Prognosis, Progression-Free Survival, Thalidomide, Transplantation, Autologous, Young Adult, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't",
author = "H Goldschmidt and Lokhorst, {H M} and Mai, {E K} and {van der Holt}, B and Blau, {I W} and S Zweegman and Weisel, {K C} and E Vellenga and M Pfreundschuh and Kersten, {M J} and C Scheid and S Croockewit and R Raymakers and D Hose and A Potamianou and A Jauch and J Hillengass and M Stevens-Kroef and Raab, {M S} and A Broijl and Lindemann, {H W} and Bos, {G M J} and P Brossart and {van Marwijk Kooy}, M and P Ypma and U Duehrsen and Schaafsma, {R M} and U Bertsch and T Hielscher and Le Jarari and Salwender, {H J} and P Sonneveld",
year = "2018",
month = feb,
doi = "10.1038/leu.2017.211",
language = "English",
volume = "32",
pages = "383--390",
journal = "LEUKEMIA",
issn = "0887-6924",
publisher = "NATURE PUBLISHING GROUP",
number = "2",

}

RIS

TY - JOUR

T1 - Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial

AU - Goldschmidt, H

AU - Lokhorst, H M

AU - Mai, E K

AU - van der Holt, B

AU - Blau, I W

AU - Zweegman, S

AU - Weisel, K C

AU - Vellenga, E

AU - Pfreundschuh, M

AU - Kersten, M J

AU - Scheid, C

AU - Croockewit, S

AU - Raymakers, R

AU - Hose, D

AU - Potamianou, A

AU - Jauch, A

AU - Hillengass, J

AU - Stevens-Kroef, M

AU - Raab, M S

AU - Broijl, A

AU - Lindemann, H W

AU - Bos, G M J

AU - Brossart, P

AU - van Marwijk Kooy, M

AU - Ypma, P

AU - Duehrsen, U

AU - Schaafsma, R M

AU - Bertsch, U

AU - Hielscher, T

AU - Jarari, Le

AU - Salwender, H J

AU - Sonneveld, P

PY - 2018/2

Y1 - 2018/2

N2 - The Dutch-Belgian Cooperative Trial Group for Hematology Oncology Group-65/German-speaking Myeloma Multicenter Group-HD4 (HOVON-65/GMMG-HD4) phase III trial compared bortezomib (BTZ) before and after high-dose melphalan and autologous stem cell transplantation (HDM, PAD arm) compared with classical cytotoxic agents prior and thalidomide after HDM (VAD arm) in multiple myeloma (MM) patients aged 18-65 years. Here, the long-term follow-up and data on second primary malignancies (SPM) are presented. After a median follow-up of 96 months, progression-free survival (censored at allogeneic transplantation, PFS) remained significantly prolonged in the PAD versus VAD arm (hazard ratio (HR)=0.76, 95% confidence interval (95% CI) of 0.65-0.89, P=0.001). Overall survival (OS) was similar in the PAD versus VAD arm (HR=0.89, 95% CI: 0.74-1.08, P=0.24). The incidence of SPM were similar between the two arms (7% each, P=0.73). The negative prognostic effects of the cytogenetic aberration deletion 17p13 (clone size ⩾10%) and renal impairment at baseline (serum creatinine >2 mg dl-1) on PFS and OS remained abrogated in the PAD but not VAD arm. OS from first relapse/progression was similar between the study arms (HR=1.02, P=0.85). In conclusion, the survival benefit with BTZ induction/maintenance compared with classical cytotoxic agents and thalidomide maintenance is maintained without an increased risk of SPM.

AB - The Dutch-Belgian Cooperative Trial Group for Hematology Oncology Group-65/German-speaking Myeloma Multicenter Group-HD4 (HOVON-65/GMMG-HD4) phase III trial compared bortezomib (BTZ) before and after high-dose melphalan and autologous stem cell transplantation (HDM, PAD arm) compared with classical cytotoxic agents prior and thalidomide after HDM (VAD arm) in multiple myeloma (MM) patients aged 18-65 years. Here, the long-term follow-up and data on second primary malignancies (SPM) are presented. After a median follow-up of 96 months, progression-free survival (censored at allogeneic transplantation, PFS) remained significantly prolonged in the PAD versus VAD arm (hazard ratio (HR)=0.76, 95% confidence interval (95% CI) of 0.65-0.89, P=0.001). Overall survival (OS) was similar in the PAD versus VAD arm (HR=0.89, 95% CI: 0.74-1.08, P=0.24). The incidence of SPM were similar between the two arms (7% each, P=0.73). The negative prognostic effects of the cytogenetic aberration deletion 17p13 (clone size ⩾10%) and renal impairment at baseline (serum creatinine >2 mg dl-1) on PFS and OS remained abrogated in the PAD but not VAD arm. OS from first relapse/progression was similar between the study arms (HR=1.02, P=0.85). In conclusion, the survival benefit with BTZ induction/maintenance compared with classical cytotoxic agents and thalidomide maintenance is maintained without an increased risk of SPM.

KW - Adolescent

KW - Adult

KW - Aged

KW - Bortezomib

KW - Chromosome Aberrations

KW - Female

KW - Follow-Up Studies

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Male

KW - Melphalan

KW - Middle Aged

KW - Multiple Myeloma

KW - Prognosis

KW - Progression-Free Survival

KW - Thalidomide

KW - Transplantation, Autologous

KW - Young Adult

KW - Clinical Trial, Phase III

KW - Journal Article

KW - Multicenter Study

KW - Randomized Controlled Trial

KW - Research Support, Non-U.S. Gov't

U2 - 10.1038/leu.2017.211

DO - 10.1038/leu.2017.211

M3 - SCORING: Journal article

C2 - 28761118

VL - 32

SP - 383

EP - 390

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 2

ER -